CAFE Comparison of Atypicals in First Episode of Psychosis
NCT ID: NCT00034892
Last Updated: 2013-01-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
INTERVENTIONAL
2002-03-31
2005-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00090012
Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics
NCT00485498
A Comparative Study of New Medications for Psychosis in Adolescents
NCT00222495
Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00103571
Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034801
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Olanzapine, risperidone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Psychotic symptoms must have persisted at least one month, and not more thn 5 years (60 months)
* Patients must have no previous history of drug treatment (greater than a total of 16 weeks) with antipsychotics
Exclusion Criteria
* Female patients who are pregnant or nursing
* Patients with a known history of mental retardation
16 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of North Carolina
OTHER
AstraZeneca
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford, California, United States
Miami, Florida, United States
Atlanta, Georgia, United States
Augusta, Georgia, United States
Chicago, Illinois, United States
Shreveport, Louisiana, United States
Boston, Massachusetts, United States
Worcester, Massachusetts, United States
Minneapolis, Minnesota, United States
St Louis, Missouri, United States
Las Vegas, Nevada, United States
Brooklyn, New York, United States
New York, New York, United States
Butner, North Carolina, United States
Chapel Hill, North Carolina, United States
Charlotte, North Carolina, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Kettering, Ohio, United States
Philadelphia, Pennsylvania, United States
Conroe, Texas, United States
Research Site
Dallas, Texas, United States
San Antonio, Texas, United States
Salt Lake City, Utah, United States
Calgary, Alberta, Canada
Halifax, Nova Scotia, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA; Comparison of Atypicals in First Episode study group. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008 Jan;69(1):106-13. doi: 10.4088/jcp.v69n0114.
Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007 Jul;164(7):1061-71. doi: 10.1176/ajp.2007.164.7.1061.
McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007 Jul;164(7):1050-60. doi: 10.1176/ajp.2007.164.7.1050.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
5077IL/0114
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.